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Abstract
To better understand off-target effects of widely prescribed psychoactive drugs, we performed a comprehensive series of
chemogenomic screens using the budding yeast Saccharomyces cerevisiae as a model system. Because the known human
targets of these drugs do not exist in yeast, we could employ the yeast gene deletion collections and parallel fitness
profiling to explore potential off-target effects in a genome-wide manner. Among 214 tested, documented psychoactive
drugs, we identified 81 compounds that inhibited wild-type yeast growth and were thus selected for genome-wide fitness
profiling. Many of these drugs had a propensity to affect multiple cellular functions. The sensitivity profiles of half of the
analyzed drugs were enriched for core cellular processes such as secretion, protein folding, RNA processing, and chromatin
structure. Interestingly, fluoxetine (Prozac) interfered with establishment of cell polarity, cyproheptadine (Periactin) targeted
essential genes with chromatin-remodeling roles, while paroxetine (Paxil) interfered with essential RNA metabolism genes,
suggesting potential secondary drug targets. We also found that the more recently developed atypical antipsychotic
clozapine (Clozaril) had no fewer off-target effects in yeast than the typical antipsychotics haloperidol (Haldol) and pimozide
(Orap). Our results suggest that model organism pharmacogenetic studies provide a rational foundation for understanding
the off-target effects of clinically important psychoactive agents and suggest a rational means both for devising compound
derivatives with fewer side effects and for tailoring drug treatment to individual patient genotypes.
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Introduction
Neuropsychiatric disorders will effect 25% of all individuals at
some point in their lives, with devastating social and economic
consequences [1]. This constellation of diseases encompasses
schizophrenia, depression, age-related memory and cognition
decline, and the degeneration of neuromuscular function. Most
prescribed psychoactive drugs are thought to primarily target
neurotransmission pathways in the central nervous system, and
thereby cause changes in perception, mood, consciousness, and
behavior. Many of these therapeutics have been developed using in
vitro assays and, as such, may have other unknown targets and
unanticipated cellular effects in vivo. For example, side effects of
antipsychotic drugs include tremors, hypotension, impotence,
lethargy, and seizures [2]. In an effort to improve efficacy and to
reduce side effects, new generations of drugs have been developed;
among these are the so-called atypical antipsychotics such as
clozapine. While clozapine is linked to a reduced risk of
neuromuscular side effects, it is associated with new side effects
such as life-threatening agranulocytosis in up to 1% of patients [3],
and, less frequently, fatal myocarditis [4–6]. As such, the
therapeutic benefit of this and other new atypical drugs remains
open to debate. For example, a comprehensive meta-regression
analysis that compared both typical and atypical drugs concluded
that atypical antipsychotics were neither more effective nor better
tolerated than conventional agents [7]. Other classes of psycho-
active drugs, such as the antidepressants, also cause numerous
undesirable side effects and the broad usage of these medications
have been questioned [8].
Surrogate genetics is an effective approach to interrogate
heterologous gene function or drug mechanism of action using
simpler model organisms [9,10]. The budding yeast Saccharomyces
cerevisae has previously been used to help elucidate the basis of
some psychiatric disorders [11–18]. For example, the expression in
yeast of mutant and wildtype forms of the Huntington’s disease
gene revealed important factors regulating the toxicity of protein
aggregates [11,15,19], and a genome-wide suppressor screen in
yeast uncovered kynurenine 3-monooxygenase as a potential new
therapeutic target for the treatment of Huntington’s disease [13].
In other studies, expression in yeast of the alpha-synclein gene
associated with Parkinson’s disease yielded a network of
interacting genes that modulate cellular toxicity [11,15,19].
Recently, the genome-wide collection of yeast gene deletion
strains has been used to generate genetic profiles of drug sensitivity
and resistance [20–26]. These profiles have uncovered unexpected
mechanisms of action for well-known drugs, such as for the anti-
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metabolite 5-fluorouracil in perturbation of rRNA processing
[22,25] and for the anti-cancer agent tamoxifen in calcium
homeostasis [26].
To better understand potential off-target effects of FDA-approved
psychoactive drugs and their analogs, we profiled 214 psychoactive
compounds in quantitative wildtype yeast growth assays and
generated genome-wide deletion sensitivity profiles for the 81 drugs
that caused overt growth defects. The sensitivity profiles for 49 of
these drugs were overrepresented for core cellular functions such as
chromatin organization, establishment of cell polarity, and mem-
brane organization and biogenesis. Our results provide a rational
foundation for personalized drug approaches and for understanding
unwanted side effects in clinically important psychoactive agents.
Results
Specific Classes of Psychoactive Drugs Have Bioactivity in
Yeast
To ask if psychoactive compounds can inhibit wildtype budding
yeast growth, we challenged yeast with 76 high-purity psychoactives
representing 16 ligand categories that encompass a broad spectrum of
treatments for neurological disorders (see Figure 1 for workflow and
Table S1 for drug information). Despite the fact that yeast lacks the
established neuronal targets of these compounds, 17/76 (22%) drugs
inhibited the growth of wildtype yeast (when tested at 200 mM) and
are hereafter referred to as ‘‘bioactive’’. This observation shows that
in addition to their reported targets, many of these compounds also
have secondary mechanisms of action. In fact, over half of the 16
tested ligand classes included compounds that were bioactive
(Figure 2A). Among these, serotonin uptake inhibitors were most
effective; four of five tested molecules in this class inhibited yeast
growth (Figure 2A). Because our assay depends on growth inhibition
in order to observe any effects on specific deletion strains, we
proceeded with the 17 bioactive compounds and determined a drug
dose that inhibited wildtype growth by,15% (Figure 2B, Table S1).
In our previous genome-wide studies this level of inhibition best
captured the ability to identify the known drug target while
minimizing the number of generally sensitive strains [22,23].
Applying this drug dose, we subjected the bioactive compounds to
genome-wide parallel fitness profiling. In this technique, pools of
deletion strains are grown competitively for several generations in the
presence of a sub-lethal concentration of drug, and genomic DNA is
extracted. After PCR-amplification of the unique molecular barcodes
incorporated into each gene deletion cassette, the relative role of each
gene for growth in the presence of drug is determined by
hybridization of the PCR products to a DNA microarray carrying
the barcode complements [27–29]. The relative abundance of
sequence tags in the drug experiments is compared to control
experiments and fitness ratios and z-scores are calculated (see
Materials and Methods). We used two pools of diploid strains: i)
heterozygous deletion strains deleted for one copy of the essential
genes (1158 strains), which often identifies compound targets through
HaploInsufficiency Profiling (HIP) [22,30], and ii) homozygous
deletion strains deleted for both copies of non-essential genes (4768
strains); thisHOmozygous Profiling (HOP) assay identifies genes that
buffer the drug target pathway [24].
Using this combination of the HIP and HOP assays we found
that only a few deletion strains (,5) exhibited significant sensitivity
to most of the 17 bioactive compounds (Figure 2C). In contrast,
several deletion strains (,50) were scored as sensitive for the a1-
adrenoceptor antagonist SR 59230A and the three selective
serotonin re-uptake inhibitors fluoxetine (Prozac), clomipramine,
and fluvoxamine (Figure 2C). Given this unexpected potency of
the serotonergic drugs in our yeast assays, we extended our
investigation to encompass pharmacologically related agents and
screened two commercially available drug libraries encompassing
95 serotonergic and 55 dopaminergic compounds. These drug
libraries contained the four FDA-approved serotonergics sertraline
(Zoloft), fluoxetine (Prozac), paroxetine (Paxil), and cyprohepta-
dine (Periactin), and the four FDA-approved dopaminergics
bromocriptine (Parlodel), clozapine (Clozaril), haloperidol (Hal-
dol), and pimozide (Orap). Based on our initial results, we
anticipated a high rate of bioactivity on yeast for these two drug
classes. Indeed, 66/150 (44%) of the serotonergic and dopami-
nergic drugs were bioactive, a significant difference compared to




Neuropsychiatric disorders such as depression and psy-
chosis affect one-quarter of all individuals during their
lifetime, and despite efforts to improve the selectivity of
psychoactive drugs, all are associated with side effects.
Drug efficacy and tolerance are known to be linked to an
individual’s genetic profile, but little is known about the
nature of this correlation due, in part, to the current
emphasis on screening compounds against targets in vitro.
Here we present a comprehensive, genome-wide effort to
understand drug effects on the cellular level using an
unbiased genome-wide assay to determine the impor-
tance of every yeast gene for tolerance to 81 psychoactive
drugs. We found that these medications perturbed many
evolutionarily conserved genes and cellular pathways,
such as those required for vesicle transport, establishment
of cell polarity, and chromosome biology. The 500,000
drug–gene measurements obtained in this study increase
our understanding of the mechanism of action of
psychoactive drugs. Specifically, this study provides a
framework to assess the next generation of psychoactive
agents and to guide personalized medicine approaches
that associate genotype and phenotype.
Psychoactive Drug Profiling
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the 22% of the initially screened drugs that represented the 16
different ligand sets (p,1027).
Physiochemical Properties Separating Active from
Inactive Drugs
The high prevalence of bioactivity in yeast prompted us to ask if
any particular psychoactive drug attribute correlated with the
ability of these compounds to inhibit wildtype yeast growth. We
first performed structural clustering of all ,220 screened
psychoactive compounds using chemical fingerprints in Pipeline
Pilot (Accelyrs, San Diego). As more than half of the resulting
clusters contained both active and inactive drugs, chemical
structure was not predictive of drug action on wildtype yeast
growth for this selection of compounds (data not shown). We next
asked if any physiochemical properties, as predicted from the
Figure 2. Serotonergic Drugs Showed Potency on Yeast. (A) Number of drugs that did (black) or did not (white) inhibit wildtype yeast growth
for each of the initial drug sets tested. (B) Titration of drug concentrations used in genome-wide screening. Wildtype yeast growth in serial dilutions
of drug was recorded as optical density every 15 min over a 25 h period. (C) Number of deletion strains that were sensitive (r.2 and z.3, see
Materials and Methods) to bioactive drug in genome-wide fitness profiles.
doi:10.1371/journal.pgen.1000151.g002
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structures, were linked to drug activity. The parameters we tested
included the number of H-bond donors and acceptors, molecular
weight, and hydrophobicity as measured by AlogP (the octanol-
water partition coefficient). These measures are important
descriptors used in the empirical parameter set known as Lipinski’s
Rule of Five [31]. In addition to the Lipinski descriptors, we tested
six other parameters relevant to drug activity: van der Waals
surface area, molecular surface area, molecular solubility, logD
(the octanol-water distribution coefficient; a combination of logP
and pKa), number of rings and number of rotatable bonds.
Principal component analysis revealed that a partition coefficient
of AlogP.3 was best able to predict drug activity (p,4.9e-13, for
details see Materials and Methods) as shown in Figure 3. A
molecular weight of .260g/mole was also indicative of an active
compound (p,3.4e-05, Figure 3). If there is a correlation between
human side-effects and conserved cellular pathways scored using
our surrogate yeast system, it is possible that an additional study
could help predict such effects based on structural features.
Genome-Wide Fitness Profiles on Bioactive Drugs
To systematically interrogate compound mechanisms of action,
we subjected the 66 bioactive serotonergic and dopaminergic
compounds to genome-wide fitness assays using the approach
described above (Figure 1). Combined with the initial set of 17
bioactive drugs, we screened a total of 81 unique drugs (two drugs
occurred in duplicate in the chemical libraries), eight of which are
used therapeutically (Table 1). Fitness ratios and z-scores for all
deletion strains are provided in Tables S2 and S3, respectively
(raw data are available at ArrayExpress, EMBL-EBI, accession
number E-MTAB-34). The genome-wide fitness profiles were
reproducible as the average correlation coefficient for the five
replicated compounds was 0.83, which is similar to the average
correlation coefficient of 0.72 reported in a previous large-scale
fitness study [23]. As an unbiased control, we calculated the
average correlation coefficient between all possible random drug
pairs in our assay. As expected, this value (0.44) was lower than the
average correlation coefficient for duplicates, but well above the
previously noted average correlation of zero for unrelated
compounds (Maureen Hillenmeyer, unpublished data). In agree-
ment with this, two-dimensional hierarchical clustering [32] did
not separate the dopaminergic and serotonergic profiles into two
distinct groups, but clearly separated drugs from these two classes
from most other compounds profiled (Figure 4). Further indicating
the general similarities between dopaminergic and serotonergic
drugs in our yeast screen, 25% of the significantly sensitive strains
(r.2, z.3, see Materials and Methods) scored in both drug
categories (Table S4).
Core Cellular Processes that Confer Resistance to
Psychoactive Compounds
To ask which cellular functions and pathways were required for
resistance to the tested drugs, we performed functional enrichment
tests using Gene Ontology (GO) annotations specifically focusing
on sensitive strains in the i) essential heterozygous, ii) homozygous
or iii) both collections (see Materials and Methods). 32 drug
sensitivity profiles were not enriched for any GO Process but the
Figure 3. Hydrophobicity and Molecular Weight Discrimination for Non-Active and Active Compounds. All compounds tested were
plotted as a function of logP and molecular weight.
doi:10.1371/journal.pgen.1000151.g003
Table 1. Examples of Therapeutic Use of the Profiled FDA-Approved Drugs.
Compound Therapeutic use
Clozapine Schizophrenia
Cyproheptadine Schizophrenia, serotonin syndrome, allergy, eating disorder
Fluoxetine Depression, obsessive compulsive disorder, bulimia nervosa
Paroxetine Depression, anxiety disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder
Sertraline Depression, obsessive compulsive disorder, post-traumatic stress disorder
Pimozide Schizophrenia, psychosis
Haloperidol Mania, bipolar disorder, schizophrenia, psychosis, nausea, vomiting, restlessness, agitation and aggression, Tourette’s syndrome and
other tic disorders, hiccups
Bromocriptine Parkinson’s, pituitary tumours, female infertility, overproduction of breast milk
doi:10.1371/journal.pgen.1000151.t001
Psychoactive Drug Profiling
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remaining 49 profiled drugs (60.5%) interfered with 106 different
processes (multiple-testing corrected p-value,0.0001, Table S5).
For visual clarity, we collapsed these 106 processes down to 22
(Table S6). The drug sensitivity profiles obtained with the
combined set of heterozygous and homozygous strains were
enriched for the highest number of condensed GO processes (119
processes, purple color in Figure 5), while 12 processes were
uniquely enriched among sensitive homozygous deletion strains
(blue color in Figure 5). These processes likely reflect drug
detoxification mechanisms (e.g. ‘‘vesicle transport’’ and ‘‘response
to drug’’) or other processes required for resistance to compound
by an unknown mechanism (e.g. ‘‘amino acid biosynthesis and
metabolism’’). Two processes were uniquely scored for essential
genes (red color in Figure 5) and are further discussed below.
Investigating the general nature of our enrichment profiles, we
found that the most frequently enriched processes across all drugs
and genetic backgrounds were vesicle transport, protein localiza-
tion, and telomere biology (Figure 5). Genes functioning in cell
morphogenesis, establishment of cell polarity, cell cycle, amino
acid biosynthesis, chromatin organization, RNA metabolism, and
membrane organization were also needed for resistance to several
(.5) of the psychoactive drugs. A few GO Processes were unique
Figure 4. Global Landscape of Fitness Profiles. Two-dimensional hierarchical clustering [32] was used to group all log2-fitness ratios obtained
from the 81 drugs. Log2-fitness ratios from 0 (no fitness defect) to 3.5 (severe phenotype) are color-coded according to the severity of the sensitivity
(this paper focuses on sensitivities, see Materials and Methods). Only 0.1% of the log2-fitness ratios were higher than 3.5 and became saturated in the
figure. The separation of dopaminergic and serotonergic drugs (orange) from drugs in other categories (grey) is indicated. Groups of strains
exhibiting highly similar fitness profiles across the psychoactive drugs are extracted from the global clustergram, and the deletion strains included in
each group are listed in the order determined by the hierarchical clustering algorithm. For each group of strains, the dominant function(s) of the
deleted genes is indicated. Essential genes are underlined.
doi:10.1371/journal.pgen.1000151.g004
Psychoactive Drug Profiling
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Figure 5. Enriched GO Processes. Significant enrichment (p,0.0001) for GO Processes uniquely scored using sensitive (z.2) homozygous strains
(blue) or heterozygous strains deleted for essential genes (red). GO Processes scored using both strain pools are indicated in purple (for details see
Materials and Methods). Dopaminergic drugs are indicated in green, serotonergic in orange, and other drugs (from the initially analyzed diverse set)
in grey. Drugs with affinity for both a dopaminergic and a serotonergic receptor are indicated according to which Tocris drug library they belong to.
Closely related GO categories are collapsed for clarity (see Table S6).
doi:10.1371/journal.pgen.1000151.g005
Psychoactive Drug Profiling
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to a single drug: protein glycosylation (A77636), methylation (SB
216641), cell wall organization and biogenesis (GR 127935), and
membrane lipid metabolic process (pimozide). In the subsequent
sections we focus on the analysis of the FDA-approved drugs and
summarize the most notable enrichments for these drugs in
Table 2. First, we discuss identified buffering pathways and drug
detoxification mechanisms. Next, we concentrate on potential new
drug targets identified for the therapeutically used psychoactive
drugs.
Uncompromised Cellular Transport, Protein Localization,
and Telomere Maintenance Is Important for Resistance to
Psychoactive Drugs
Vesicle transport was the most commonly overrepresented
process among genes required for resistance to psychoactive drugs
(Figure 5) suggesting that uncompromised vesicle transport
function is a general requirement for psychoactive drug detoxifi-
cation. The enrichment of cellular transport genes was especially
pronounced in response to clozapine treatment, where 9 of the 10
most required genes belonged to this category (Table 3). Protein
sorting and localization accounted for the second most frequently
enriched process (Figure 5). Deletion of vesicle trafficking and
protein localization genes often resulted in very severe phenotypes
(bright yellow in Figure 4). Gene products with protein localization
roles include those involved in selecting cargo proteins for
endosome-to-Golgi retrieval (e.g. Vps29), and those involved in
sorting proteins in the vacuole (e.g. Pep8). Interestingly, the fitness
profiles obtained with certain vesicle transport and protein
localization deletions clustered with those obtained with strains
deleted for genes functioning in actin filament organization/
stabilization (arc18D, tpm1D, vrp1D,), mRNA degradation (lsm1D),
and stabilization of membrane amino acid transporters (npr1D)
(Figure 4, left text panel). A second, large group of strains mainly
deleted for genes functioning in vesicle transport and protein
localization exhibited similar phenotypes across the 81 drugs as
ckb1D and ckb2D, which are deleted for genes functioning in
regulation of transcription and mitotic cell cycle (Figure 4, right
panel).
Most of the drug sensitivity profiles were enriched for both
protein localization and telomere biology (Figure 5). The apparent
‘‘linking’’ of these enrichments could be attributed to genes that
are, in fact, involved in both these processes. Examples of such
genes function in the three Endosomal Sorting Complexes
Required for Transport, more specifically in ESCRT I (VPS28,
STP22), in ESCRT II (SNF8 and VPS25), and in ESCRT III
(SNF7). These genes are, in addition, associated with telomere
defects [33,34].
The Atypical Antipsychotic Clozapine Has No Fewer Off-
Target Effects than Typical Antipsychotics
Because the more recently developed atypical antipsychotic
drugs are still associated with side effects and their benefits are
currently debated, we compared the phenotypic profiles of the
atypical antipsychotic clozapine to two traditional antipsychotics,
reasoning that if atypical drugs are more specific, they would
exhibit fewer off-target effects in yeast. In contrast to this
expectation, the atypical antipsychotic clozapine exhibited a
similar number of significantly sensitive (r.2, z.3, see Materials
and Methods) deletion strains (26) as the typical antipsychotic
drugs pimozide (29) and haloperidol (20). Comparing the fitness
profiles of clozapine with the typical antipsychotics pimozide and
haloperidol, we found that each drug was associated with unique
functional enrichment profiles: clozapine for telomere biology and
Table 2. Most Notable Off-Target Effects of FDA-Approved
Drugs.
Drug Functional enrichment (p,0.0001)*
Clozapine Vesicle-mediated transport
Cyproheptadine Chromatin-remodelling
Fluoxetine Establishment of cell polarity
Paroxetine RNA processing
Sertraline Vesicle-mediated transport
Pimozide Membrane lipid metabolic process
Haloperidol Aromatic amino acid biosynthesis
Bromocriptine Aromatic amino acid biosynthesis
*Italics = unique enrichment among FDA-approved drugs.
doi:10.1371/journal.pgen.1000151.t002
Table 3. Top-Ten Sensitive Deletion Strains in Genome-Wide Profiles of FDA-Approved Serotonergic and Dopaminergic Drugs*.
Clozapine Cypro-heptidine Fluoxetine Paroxetine Sertraline Pimozide Halo-peridol
NEO1 V NEO1 V NEO1 V NEO1 V NEO1 V MCD4 NEO1 V
PEP7 V ARP4 D RPL32 R TOA2 R CCT7 P GSP1 R TRP4 A
VPS35 V PEP12 V TCP1 P CFT1 R RPL32 R PEP12 V ARP4 D
PEP12 V TUB1 P VPS30 V SEC4 V GSP1 R TUB4 P ERG11
SAC1 V CCT7 P CAP2 P CCT8 P NOP8 R SEC22 V ARO2 A
VPS29 V VPS35 V PEP12 V RPL32 R BET1 V PGD1 R APL2 V
PEP8 V CCT3 P CCT3 P FHL1 R ARP4 D THP2 R ARO1 A
VPS20 V CCT4 P MRS5 V GSP1 R NUS1 V PIK1 RCY1
NHX1 VPS30 V PEP8 V GCD11 R CCT3 P YPK1 VPS29 V
LEM3 V VPS29 V DFR1 RHO1 PEP12 V PEP7 V PIK1
*Essential genes are in bold, and gene functions that occur frequently in the table are indicated with letters. V = vesicle transport, protein transport and localization,
D =DNA repair, P = protein folding, actin and tubulin assembly, R = RNA processing, transcription, translation, ribosomal function, A = amino acid biosynthesis and
metabolism. For bromocriptine, we scored only one significantly sensitive strain, trp3D, which is involved in aromatic amino acid biosynthesis (z.3, r.2). Strains were
sorted according to their fitness ratio, using average ratios for replicated drugs and removing dubious ORFs.
doi:10.1371/journal.pgen.1000151.t003
Psychoactive Drug Profiling
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protein localization, pimozide for membrane lipid metabolic
processes, and haloperidol for aromatic amino acid biosynthesis
and metabolism (Figure 5). In contrast, vesicle transport was
enriched in all three drug sensitivity profiles. The more detailed
GO processes behind the condensed process vesicle transport were
vesicle-mediated transport for all three drugs and, in addition,
secretory pathway, secretion, post-Golgi vesicle-mediated trans-
port and Golgi vesicle transport for haloperidol and clozapine
(Tables S5 and S6). The distinct fitness profiles are consistent with
the structural differences that exist between these drugs (Figure
S1). For example, clozapine has substructures (piperazine and
diazepine) that do not exist in pimozide and haloperidol, and
haloperidol contains two benzene rings while pimozide has three.
Bromocriptine, Haloperidol, and Five Additional
Dopaminergic Drugs Interfere with Amino Acid
Biosynthesis and Metabolism
Compared to the other investigated therapeutics, the fitness
profile in the anti-Parkinson drug bromocriptine pointed to a
single potential off-target mechanism of action for this drug. The
only overrepresented function among sensitive strains was amino
acid biosynthesis and metabolism (Figure 5) and the most sensitive
strains were deleted for the aromatic biosynthesis genes TRP3,
TRP4, TRP1, ARO1, TRP2, and ARO2. In addition to bromocrip-
tine, six other dopaminergic drugs also interfered with amino acid
biosynthesis and metabolism (Figure 5). The sensitivity profiles of
all these seven drugs shared the enrichment for the detailed GO
process aromatic compound metabolic process (Tables S5 and S6)
due to the sensitive phenotype of 13 strains in total. Among them,
strains deleted for TRP1, TRP2, TRP3, TRP4, TRP5, ARO2, and
ARO3 were scored in all 7 drugs and strains deleted for ARO1 and
ARO7 in 6 drugs. Besides the notable enrichment for genes
involved in aromatic compound metabolism, the sensitivity of
strains missing other genes also contributed to the observed GO
process enrichment. Such genes included the folic acid (vitamin
B9) biosynthesis gene FOL2, the panthothenate (vitamin B5,
precursor of coenzyme A) biosynthesis gene FMS1, and the protein
kinase GCN2, which induces amino acid biosynthesis genes in yeast
in response to starvation and, in addition, restricts intake of diet
lacking essential amino acids in rats [35].
Pimozide Is Unique in Being Enriched for Membrane
Lipid Metabolic Process Genes
The sensitivity profile of the typical antipsychotic pimozide
showed a unique enrichment for membrane lipid metabolic
processes not seen for any of the other 80 profiled drugs (Figure 5).
In pimozide, the MCD4-deletion strain had the strongest
phenotype and was 21-fold depleted compared to the control
(Table 3). MCD4 is highly conserved among eukaryotes and
functions in glycosyl-phosphatidylinositol (GPI) anchor synthesis.
Because MCD4 is an essential gene, it may represent an additional,
clinically relevant drug target for pimozide. The inositol-lipid-
mediated signaling gene PIK1 and the spingholipid-mediated
signaling gene YPK1 were also among the ten most required genes
for resistance to pimozide (Table 3). They clustered with a group
of other strains deleted for genes involved in lipid biology
(Figure 4), such as the de novo lipid synthesis genes PAH1 and SUR4.
Fluoxetine Interferes with the Establishment of Cell
Polarity
Eight drugs, among them the antidepressant fluoxetine, were
enriched for the condensed term establishment of cell polarity
(purple or blue color in Figure 5). In total, 51 genes were assigned
to the detailed GO process establishment and/or maintenance of
cell polarity and caused a sensitive phenotype when deleted
(Tables S5 and S6). Many of these genes scored in the majority of
the drugs, for example all four members (CKA1, CKA2, CKB1, and
CKB2) of the casein kinase II-holoenzyme complex, and TPM1,
the major isoform of tropomyosin which directs polarized cell
growth and organelle distribution. For the seven drugs where the
enrichment for establishment and/or maintenance of cell polarity
was scored using sensitive homozygous and essential heterozygous
strains (purple color in Figure 5), six essential members (EXO70,
SEC3, SEC6, SEC8, SEC10 and SEC15) of the exocyst complex,
which determines where secretory vesicles dock and fuse, were
scored in all drugs except fluoxetine.
Essential Genes of High Importance for Drug Resistance
May Reveal Additional Secondary Drug Targets for
Psychoactive Drugs
Drug targets are often encoded by essential genes, thus essential
genes scored in our assay may represent important additional
targets of psychoactive compounds that may be useful in the
development of therapeutics for other applications. In a given
heterozygous strain, the reduced gene copy number of a potential
drug target leads to a reduced level of the corresponding protein.
When this strain is grown in the presence of a drug targeting the
heterozygous locus, the result is a further decrease in ‘‘functional’’
dosage due to the drug binding to the protein target. If this protein
is important for growth, the result will be drug sensitivity [22]. In
our functional enrichment tests, two processes were uniquely
overrepresented among sensitive essential genes (red color in
Figure 5): mitotic and meiotic cell cycle for fluorophenyl-
methoxytropane and chromatin organization for cyproheptadine.
Examples of targeted essential genes in cyproheptadine treatment
include chromatin-remodeling genes (ARP4, ARP7, ARP9), genes
in the multisubunit (NuA4) histone acetyltransferase complex
(EPL1, ESA1, SWC4), and RSC4 and RSC6 in the RSC Chromatin
remodeling complex.
Although not revealed as a functional enrichment among
sensitive strains deleted for essential genes, most of the other FDA-
approved drugs also have potential secondary drug targets as
infered by the presence of essential genes among the ten most
required genes for drug resistance (Table 3). As judged by the high
number of sensitive strains deleted for essential genes in paroxetine
treatment (10 strains) and sertraline treatment (9 strains), these
selective serotonin re-uptake inhibitors are particularly rich in
potential secondary drug targets. Essential genes required for
resistance to the FDA-approved drugs include those involved in
RNA processing, transcription and translation, genes functioning
in the protein folding chaperonin complex, and the chromatin-
remodeling/DNA repair gene ARP4 (bold in Table 3). Deletion of
ARP4 resulted in some of the most sensitive phenotypes when cells
were treated with cyproheptadine, sertraline, or with haloperidol
(Table 3). ARP4 has a close human homolog, ACTL6B, which
encodes a subunit of the BAF (BRG1/brm-associated factor)
complex in mammals, functionally related to the SWI/SNF
complex in S. cerevisiae. The SWI/SNF complex is thought to
facilitate transcriptional activation by antagonizing chromatin-
mediated transcriptional repression [36]. Another example of an
essential gene required for drug resistance in several FDA-
approved drugs is GSP1, which functions in RNA-processing
(Table 3). The mammalian homolog of Gsp1, Ran (BlastP E-
value,E-261) is, as in yeast, a nuclear GTP-binding protein.
Interestingly, the fitness profile of the ARP4-deleted strain was
very similar to the strains deleted for the cytosolic chaperonin
subunits CCT5, CCT8 and TCP1 (Figure 4). The chaperonin
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complex is involved in protein folding (primarily of actin and
tubulin) and cytoskeleton organization [37]. In our fitness assays,
seven of eight CCT-strains scored as significantly sensitive in many
of the probed psychoactive drugs. Some (CCT3, CCT4, CCT7 and
CCT8) were even among the top-ten required genes for resistance
to cyproheptadine, fluoxetine, paroxetine, and sertraline (Table 3).
Furthermore, several deletion strains with uncharacterized func-
tions had similar fitness profiles as the chaperonins CCT5, CCT8
and TCP1 (Figure 4). Among them were TVP23 and YIP5 which
both localize to the late Golgi, YEL048C which is synthetic lethal
with GCS1 (involved in ER to Golgi transport), APM2 (homologous
to medium chain of mammalian clathrin-associated protein
complex involved in vesicle transport) and SWH1 (similar to
mammalian oxysterol-binding protein, localized to Golgi and
nucleus-vacuole junction).
Psychoactive Drugs often Impinge on Evolutionarily
Conserved Processes
To test if our findings in yeast might reflect drug action in
human cells, we looked at the proportion of scored genes with
human homologs. Among the strains significantly sensitive to at
least one psychoactive compound, 58.4% were deleted for a gene
with a close human homolog (BlastP E-value,E-6), as compared
to 45.0% for all analyzed deletion mutants regardless of whether
they had a fitness defect or not. To test if strains deleted for genes
involved in core cellular processes are more sensitive in general, we
compared our results obtained with the 81 psychoactive
compounds to 81 randomly chosen chemically diverse compounds
(see Materials and Methods). We found that a similar proportion
of genes with close human homologs (59.7%) were scored for
strains that were significantly sensitive to at least one of these
diverse chemicals. Despite this similarity in proportion of sensitive
strains with human homologs in the two datasets, conserved genes
were scored much more frequently (in .10% of the compounds)
in the psychoactive drug set than in the random drug set. In fact,
considering only genes deleted in frequently scored strains, 64.1%
of the psychoactive drugs had close human homologs (BlastP E-
value,E-6) while the corresponding proportion for the structur-
ally diverse drug set was significantly (p,0.006) lower (45.4%) and
similar as the fraction of human homologs for multi-drug
resistance genes (47.1%) in a recently published study [23]. This
difference points to a significant enrichment of frequently scored
sensitive strains with human homologs for the psychoactive drugs.
Among the strains sensitive to the highest number of psychoactive
compounds, seven of eight had close human homologs: NEO1,
SAC1, PIK1, VPS29, PEP8, ARP4 and VPS35. The majority of
these genes are involved in vesicle transport, which was the most
frequently enriched function among strains sensitive to psychoac-
tive drugs. Thus, the specific psychoactive drug detoxification
mechanisms identified in yeast are likely to be of importance in
humans treated with psychoactives.
Discussion
Many psychoactive drugs are associated with adverse secondary
effects in humans yet the mechanisms that underlie these off-target
effects are poorly understood. To address mechanisms of drug
action in a systematic manner, we profiled the genome-wide
collection of budding yeast deletion strains for sensitivity to a
broad spectrum of psychoactive compounds, of which dopami-
nergic and serotonergic drugs had a high bioactivity. Among 214
tested compounds, we uncovered 81 drugs that conferred a
measurable growth defect on wildtype yeast. An appropriate dose
of these active compounds was applied to the pooled heterozygous
and homozygous yeast deletion sets to identify genes whose
function is required for optimal growth in the presence of drug.
Fifteen percent of all yeast strains (deleted for non-dubious ORFs)
exhibited significant sensitivity (r.2, z.3) to these 81 psychoactive
compounds and more than half of the drugs interacted with core
cellular functions. Several clinically important drugs, such as
fluoxetine, cyproheptadine, and clozapine were linked to diverse
cellular processes. This observation may explain both the diversity
of side effects observed in human patients and the therapeutic
variability associated with these drugs. That is, polymorphisms in
any of the conserved processes affected by a given drug are a likely
source of the individual variation in response to drug. For instance,
the response to the frequently prescribed antipsychotic clozapine is
highly variable between individuals as the same dose can have
markedly different efficacy and/or side effects in different patients
[38]. Genes functioning in vesicle transport, protein localization,
telomere biology, and catabolic processes were required for
clozapine resistance in yeast. In another example, fluoxetine is
associated with side effects such as seizures, nausea, sleepiness,
anxiety, and serious allergic reactions. This antidepressant affects
numerous cellular processes including establishment of cell
polarity, protein localization, and cytoskeleton organization and
biogenesis. Given the limited number of FDA-approved drugs
within the set of 81 compounds analyzed here and the overlapping
side effects associated with these drugs, it is not yet possible to
correlate any single side effect to a particular perturbed pathway.
The most frequently scored sensitivity for the 81 profiled
antipsychotic drugs was due to loss of secretory pathway function,
likely indicating the importance of vesicle transport (e.g. to the
vacuole) for drug detoxification. The lysosome (the mammalian
vacuole equivalent) is known as the major site of degradation of
both exogenous and endogenous molecules. For FDA-approved
drugs, the requirement for vesicle transport genes was reflected in
the frequent sensitivity of the neo1 deletion strain as the most
sensitive strain in six FDA-approved drugs. Neo1 is an essential,
highly conserved type 4 P-type ATPase involved in intracellular
membrane- and protein-trafficking. Members of this family of P-
type ATPases are implicated in the translocation of phospholipids
from the outer to the inner leaflet of membrane bilayers. Our data
suggested that interference with membrane structure and transport
through inhibition of Neo1 is an additional, unwanted mechanism
of action for clozapine, cyproheptadine, fluoxetine, paroxetine,
sertraline and haloperidol, and their drug analogs. The impor-
tance in humans of functional 4 P-type ATPases is well
documented as hereditary cholestasis, caused by defects in biliary
epithelial transporters, has been directly linked to mutations in a 4
P-type ATPase gene [39].
In addition to the frequently observed requirement for
uncompromised vesicle transport for drug detoxification, several
drug sensitivity profiles were enriched for more specific processes.
Within the FDA-approved drug group, the antidepressant
paroxetine was unique in targeting RNA processing genes,
pimozide interfered with membrane lipid metabolic processes,
cyproheptadine preferentially targeted essential genes with chro-
matin remodelling functions, and fluoxetine interfered with
establishment of cell polarity. Furthermore, seven dopaminergic
compounds including the anti-Parkinson drug bromocriptine
resulted in sensitivity of strains deleted in aromatic amino acid
biosynthetic genes. This sensitivity may be a result of that
dopaminergic drugs block aromatic amino acid uptake in yeast,
requiring yeast to activate the corresponding biosynthetic
pathways. Given the fact that aromatic amino acids are precursors
to dopamine and serotonin, this was an interesting observation
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suggesting that the levels of intracellular precursors may be
important in the response to certain psychoactive drugs.
Interestingly, interference with members of the chaperonin
complex resulted in some of the most severe phenotypes. Seven of
eight CCT-strains scored as significantly sensitive in several
psychoactive drugs, among them CCT5. The human homolog of
this gene is associated with hereditary neuropathy [40]. Although
it is unclear how mutated CCT5 causes this disease, it has been
postulated that its mutation leads to accumulation of misfolded
cytoskeletal proteins, leading to defective assembly of actin into
microfilaments resulting in neuronal apoptosis [41]. In our yeast
screens, CCT5 was needed for resistance to eight different
compounds (cyproheptadine, paroxetine, fluoxetine, indatraline,
MDL72222, CY208-243, 2-Chloro-11-(4-methylpiperazino)-di-
benz[b,f]oxepin, N-Desmethyl-clozapine, and 3-alpha-[(4-Chlor-
ophenyl)-phenylmethoxy]-tropane. We conclude that interference
with tubulin and actin folding is an important, secondary
mechanism of action of these compounds.
As an example of how the information from our yeast assays
may lead to testable drug-gene interaction hypotheses in humans,
we found that the levels of the yeast strain heterozygous for ACC1
was eleven-fold reduced in ritanserin as compared to the control,
indicating that the acetyl-CoA carboxylase Acc1 may be a
secondary target of ritanserin. Like its yeast counterpart, the
human homolog ACACA is required for de novo biosynthesis of long-
chain fatty acids and its activity drops during fasting [42]. Because
increased appetite is a reported side-effect during ritanserin
treatment [43], it is tempting to speculate that biochemically
mimicking fasting would increase appetite.
These studies raise several important issues for further
consideration. Understanding the mechanisms that underlie
adverse effects of clinically approved drugs is crucial for the
development of next generation therapeutics with improved
selectivity and efficacy. Moreover, knowledge of patient polymor-
phisms in off-target pathways may allow adverse effects of any
given drug to be preempted by personalized pharmacogenomic
strategies. It is also conceivable that some of the observed
secondary drug effects are critical for therapeutic benefit.
In summary, a number of cellular processes were associated
with sensitivity to the dopaminergic and serotonergic classes of
psychoactive compounds. This points to additional, previously
uncharacterized mechanisms of action for these drugs in humans
and suggests follow-up experiments aimed at understanding a
drug’s mechanism of action on a genome-wide level. Our results
suggest that model organism pharmacogenetics can be used as a
comprehensive and unbiased tool in initial studies aiming at
unraveling secondary effects and mechanisms of action for
therapeutic compounds and their analogs. A more rigorous
understanding of the complete mechanism of drug action in
humans would be beneficial in the development of a new




High purity compounds for genome-wide fitness profiles were
obtained from Tocris BioScience (http://www.tocris.com) as
ligand sets and as the serotonergic (#1732) and dopaminergic
(#1718) collections. In total, these drug collections comprised 226
drugs, 12 of which overlapped between the collections. A complete
list of drugs, catalogue numbers, solvents, and concentration used
in the genome-wide screens is provided in Table S1.
Genome-Wide Yeast Growth Assay
For genome-wide fitness profiles, the complete sets of ,4700
homozygous deletion strains and ,1100 essential heterozygous
deletion strains in the BY4743 and BY4744 backgrounds (MATa/
a his3D1/his3D1 leu2D0/leu2D0 lys2D0/LYS2 MET15/met15D0
ura3D0 /ura3D0 ORF::kanMX4) were used [29,44]. A strain in the
same genetic background with YDL227C replaced by kanMX4 was
used as the wildtype control for drug titration curves. Strains were
stored in 7% DMSO at -80uC. Because all experiments were
performed in rich media (YPD [45], without antibiotics), it is
unlikely that the presence of auxotrophies had a major effect on
our results, however, we cannot rule out that the disruption of the
corresponding pathways in yeast may, in some cases, alter our
findings. Beginning from an initial maximal concentration of
200 mM, the degree of growth inhibition was determined by
exposing wildtype cells to a serial dilution of compound until only
a slight inhibition (,15%) of wildtype growth was observed (see
Figure S1). Cells were inoculated at an OD600 of 0.0625 in serial
dilutions of drug and grown in a Tecan GENios microplate reader
(Tecan Systems Inc., San Jose, USA) at 30uC with orbital shaking.
Optical density measurements (OD600) were taken every 15 min-
utes until the cultures were saturated, and doubling time (D) was
calculated as described [46]. Fitness assays using pooled deletion
strains were performed as described [47] with the following
modifications: i) after growth, 350 ml from each of two
independent cultures of the 5-generation homozygous pool and
350 ml from the 20-generation heterozygous essential pool were
combined, thereby allowing for approximately equal representa-
tion of barcodes for PCR reactions and hybridization to the same
DNA chip using the unique barcodes incorporated in each of these
strains. ii) for amplification of the tags, ,0.2 mg genomic DNA
was combined with a 1 mM mix of either up- or down-tags and
82% (v/v) Platinum High Fidelity PCR Supermix (Invitrogen #
11306-016) containing anti-Taq DNA polymerase antibody,
Pyrococcus species GB-D thermostable polymerase, recombinant
Taq DNA polymerase, Mg2+, and dNTPs, iii) extension temper-
ature was 68u, iv) extension was for 2 min except for a final 10 min
extension v) 34 cycles of amplification were performed, vi) after 10-
16 h, the hybridization mix was removed from Affymetrix Gene
Chips, replaced with Wash A (6x SSPE, 0.01% Tween), and chips
were stained and washed using GeneChip Fluidics Station 450
(Affymetrix) according to the GeneFlex_Sv3_450 protocol with
one additional wash A cycle before the staining.
Data Analysis
Intensity values for the probes on the chip were extracted using
the GeneChip Operating Software (Affymetrix). Quantile normal-
ization, outlier omission, fitness defect ratio (denoted as ‘‘r’’) and z-
score (denoted as ‘‘z’’) calculations were performed as previously
described [47,48]. In short, fitness defect ratios were calculated for
each deletion strain as the log2 of the ratio between the mean
signal intensities of the control and the drug chips. The larger the
ratio, the more depleted (sensitive) is the strain as compared to
control condition without the drug. To include the variance in the
control experiments, we also calculated z-scores for each gene by
dividing the difference in mean intensity across the control chips
and treatment with the mean standard deviation of the signal
intensities for the given gene across all 18 control chips [48]. The
larger the z-score, the more likely it is that a given strain is
significantly depleted from the pool. In our analysis, we scored a
deletion strain as significantly sensitive using a threshold for both
z-score and log2 intensity ratio. A threshold of z.3 was selected
based on our earlier observations that above this limit, 100% of
186 deletion strains detected as sensitive by microarray could be
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confirmed using individual growth assays [24]. This stringent
threshold was chosen to minimize the number of false positives. In
addition, we added a further requirement that a sensitive strain
should display at least a fourfold depletion (r.2, i.e. log2.2)
compared to the control condition. This criterion was added to
avoid including z-scores which were artificially high due to a low
standard deviation in the control chips. Due to the way the screens
were performed (at low drug concentration, i.e. an IC15) and
analyzed [22,24] we have focused on sensitive strains in this work,
as opposed to apparently resistant strains. Two-dimensional
hierarchical clustering of the fitness ratios was performed using
Pearson correlation [32] and the data was visualised using the
MultiExperiment Viewer from the TM4 microarray software suite
(http://www.tm4.org/index.html).
In each of the 81 profiled drugs, sensitive deletion strains were
tested for Gene Ontology Functional enrichment using the
standard hypergeometric test provided by the GoStats Biocon-
ductor modules for R [49]. For each drug, we performed three
independent functional enrichment tests using i) sensitive hetero-
zygous strains deleted for essential genes (z.2), ii) sensitive
homozygous strains (z.2), and iii) all sensitive strains in the given
drug with z.2. As the global control set, we used all yeast ORFs in
the corresponding deletion background with chip intensity values
above background. The background was determined as the
average value of all unused tags on the chip (,3600 tags65
copies = 18000 values) +2 standard deviations of the background
tags. Obtained p-values were corrected for multiple testing by
multiplying by the number of identified terms. Adjusted p-
values,0.0001 were considered significant. GO processes linked
to less than 20 or more than 300 genes in our background set were
excluded from our tests. Two-dimensional hierarchical clustering
of overrepresented GO processes was performed using binary data
[50]. To test the robustness of our functional enrichment tests, we
repeated the same analysis using each of the following thresholds:
z.3, r.2, r.3 and found consistent functional enrichment
profiles.
In the calculations of the proportion sensitive strains deleted for
genes with close human homologs (Blastp E-value,E-6), we used a
set of 81 recently profiled (our unpublished data) compounds with
potency against wildtype yeast. These compounds represent
structurally diverse chemicals derived from Chemical Diversity
Labs, Inc. repository of .500,000 compounds.
Structure data files were obtained from Tocris and Pubchem for
all compounds and Babel canonical smile strings were generated.
In the chemical structure clustering, extended connectivity
fingerprints based on functional classes in Pipeline Pilot were used
[51]. In the physiochemical property clustering, ten descriptors
representing important properties for potential drug candidates
were calculated after salts were stripped, using Frowns and
Openeye cheminformatic libraries [31,52]. PCA was used to find
the strongest properties that separated active from non-active
compounds. The revealed properties ALogP and molecular weight
were validated to see how they correlated with the pattern of the
other eight descriptor loadings. The non parametric Wilcoxon
rank sum test supported LogP (p-value 4.91e-13) and MW (p-value
3.42e-05) as significant representative properties.




Figure S1 Chemical structures of the atypical antipsychotic
clozapine and the typical antipsychotics haloperidol and pimozide.
Found at: doi:10.1371/journal.pgen.1000151.s001 (0.80 MB TIF)
Table S1 Drugs used in genome-wide fitness profiles. Catalogue
number (Tocris), solvent, highest drug concentration tested in
wildtype yeast, drug concentration used, and brand names for
FDA-approved drugs.
Found at: doi:10.1371/journal.pgen.1000151.s002 (0.04 MB
XLS)
Table S2 Fitness ratios for indicated compounds for all deletion
strains with intensity values above background.
Found at: doi:10.1371/journal.pgen.1000151.s003 (9.73 MB
XLS)
Table S3 Z-scores for the indicated compounds for all deletion
strains with intensity values above background.
Found at: doi:10.1371/journal.pgen.1000151.s004 (9.73 MB
XLS)
Table S4 Strains scored as significantly sensitive with at least one
dopaminergic or one serotonergic drug. For each strain, the
number of dopaminergic and serotonergic drugs that caused
significant depletion in the pool is shown (r.2, z.3). Strains
scored in both drug classes are indicated with "1".
Found at: doi:10.1371/journal.pgen.1000151.s005 (0.33 MB
XLS)
Table S5 Significantly enriched (p,0.0001) GO Processes in
genome-wide fitness profiles.
Found at: doi:10.1371/journal.pgen.1000151.s006 (0.12 MB
XLS)
Table S6 Sub-grouping of the enriched GO categories.
Found at: doi:10.1371/journal.pgen.1000151.s007 (0.02 MB
XLS)
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